Structural Heart Occluders

This channel includes news and new technology innovations about structural heart occluders. These include information of surgical repair and transcatheter closure of PFO, VSD, ASD and LAA. Devices include the Amplatzer and the Gore Helex

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell

Blog | Structural Heart | April 21, 2021
As a medical technology journalist, a little more than a decade ago I found myself sitting in those late afternoon "...
The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

The reSept ASD Occluder is the first occluder with a metal-free, bioresorbable frame. It is designed to overcome the limitations of current transcatheter occluders by reducing the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.

News | Structural Heart Occluders | April 20, 2021
April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational...
Videos | Structural Heart | March 23, 2021
Interview with Scott E. Kasner, M.D., who served as the principle investigator for the Gore Cardioform REDUCE trial,...
The Teleflex Manta large-bore vascular closure device can seal holes between 12 and 25 French.

The Teleflex Manta large-bore vascular closure device can seal holes between 12 and 25 French. 

Feature | Hemostasis Management | March 09, 2021 | Dave Fornell, Editor
While many cardiac and vascular procedures have largely moved to minimally invasive techniques, the size of these...
Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect
News | Left Atrial Appendage (LAA) Occluders | October 16, 2020
October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage...
An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture. #TCT2020 #TCTconnect

An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture.

News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial...
Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization.

Boston Scientific recently introduced the newst iteration of LAA occluder device, the Watchman FLX. It uses small spikes to help better anchor the device and prevent embolization. Read more on this FDA approval.

News | Left Atrial Appendage (LAA) Occluders | August 21, 2020
August 21, 2020 — According to a report published by Research Dive, the rising number of patients suffering from atrial...
The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy. #LAA #LAAC

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy.

News | Left Atrial Appendage (LAA) Occluders | August 06, 2020
August 6, 2020 – Conformal Medical Inc. announced it secured $85 million in Series C financing to support the company’s...
Videos | Left Atrial Appendage (LAA) Occluders | July 24, 2020
Devi G. Nair, M.D., FHRS, director of cardiac electrophysiology, St. Bernards Heart and Vascular Center, Jonesboro, Ark...
The U.S. Food and Drug Administration (FDA) has approved Boston Scientific's next generation Watchman FLX Left Atrial Appendage Closure (LAAC) Device.
News | Left Atrial Appendage (LAA) Occluders | July 22, 2020
July 22, 2020 — The U.S. Food and Drug Administration (FDA) has approved Boston Scientific's next generation Watchman...
The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach
News | Cardiovascular Clinical Studies | July 01, 2020
July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (...
Videos | HRS | May 22, 2020
Interview with Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of...
Videos | Structural Heart Occluders | March 24, 2020
Interview with Carey Kimmelstiel, M.D., FACP, FACC, director, cardiac catheterization laboratory, director,...
Videos | Structural Heart | February 27, 2020
Charles D. Resor, M.D., MSc, assistant director, cardiac catheterization lab, Tufts Medical Center and assistant...
The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib). 
News | Left Atrial Appendage (LAA) Occluders | February 03, 2020
February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess...